Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development
Search Refinements
Search Results: Drug Discovery & Development
1-15 of 5521 results
University of Dundee secures grant to discover new antibacterial drugs
University of Dundee in the UK has been awarded almost £1m to boost efforts to identify new new antibiotics to tackle bacterial infections.
Drug Research > Drug Discovery & Development > News
Ignyta to explore strategic options for cancer candidate taladegib
Ignyta is exploring strategic options for taladegib and has entered into an amended and restated license, development and commercialization agreement with Eli Lilly and Company for the taladegib oncology program.
Drug Research > Drug Discovery & Development > News
BioLineRx acquires UK cancer immunotherapeutics company Agalimmune
Clinical-stage biopharmaceutical firm BioLineRx has purchased Agalimmune, a private UK-based company with an anti-cancer immunotherapy platform.
Drug Research > Drug Discovery & Development > News
GSK, Regeneron to mine gene data from 500000 volunteer participants in UK
Regeneron Pharmaceuticals announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource.
Drug Research > Drug Discovery & Development > News
Pierre Fabre, H-Immune partner on immuno-oncology therapeutics
French pharma Pierre Fabre has entered into a strategic research partnership with H-Immune to develop immuno-oncology therapeutics using the latter’s technology platform to generate lead candidates of fully human antibodies.
Drug Research > Drug Discovery & Development > News
X-Chem, Ono to collaborate on multi-target drug discovery
X-Chem, a biotechnology firm focused on developing novel small molecule therapeutics by applying its innovative drug discovery platform, has entered into a partnership with Ono Pharmaceutical.
Drug Research > Drug Discovery & Development > News
SalvaRx to invest in Rift Biotherapeutics
SalvaRx, a subsidiary of SalvaRx Group, has agreed to invest in Delaware-based biotechnology company Rift Biotherapeutics which focuses on the development of antibodies for use in oncology.
Drug Research > Drug Discovery & Development > News
Circassia signs deal for US rights to two AstraZeneca COPD drugs
By PBR Staff Writer
UK-based Circassia Pharmaceuticals has agreed to pay up to $230m for certain US commercial rights for Tudorza and Duaklir, two drugs developed by AstraZeneca to treat chronic obstructive pulmonary disease (COPD).
Drug Research > Drug Discovery & Development > News
FlexyCUBE Product Catalog
| By SYSTAG
SYSTAG - Your Partner in Chemical Development
Drug Research > Drug Discovery & Development > White Papers
FlexyCUBE - for parallel process optimisation
The Modular Tool Tailored to Suit any Laboratory Automation Needs
Drug Research > Drug Discovery & Development > Products
ePAT logging - online trend & data capture
ePAT – for various reactions and processes Quick, easy, inexpensive
Drug Research > Drug Discovery & Development > Products
FlexyPAT - Covers all your automation needs
FlexyPAT – Reactors can be automated individually Functional – cost-optimised – user-friendly
Drug Research > Drug Discovery & Development > Products
Cell Medica raises £60m to advance multiple cancer programmes
Cellular immunotherapy company, Cell Medica has secured £60m in a Series C financing round with participation from existing investors Touchstone Innovations, funds managed by Woodford Investment Management, and funds managed by Invesco Perpetual.
Drug Research > Drug Discovery & Development > News
Scientists link noncoding genetic variants to neurodevelopmental disorders
Scientists from the Max Planck Institute for Psycholinguistics and Radboud University in Nijmegen found that genetic variation in the non-coding DNA may lead to language impairments in children and other neurodevelopmental disorders such as schizophrenia, autism, and bipolar disorder.
Drug Research > Drug Discovery & Development > News
CRISPR Therapeutics licenses cell engineering platform from MaxCyte
CRISPR Therapeutics and Casebia Therapeutics, its joint venture with Bayer, have signed a licensing agreement for a cell transfection platform from MaxCyte.
Drug Research > Drug Discovery & Development > News

PBR Supplier Recommendations

Biovian - cGMP Contract Manufacturing of Biopharmaceuticals
Biovian is a dynamic and effective new generation one-stop-shop CMO in cGMP contract manufacturing of biopharmaceuticals. Biovian's services cover the full range from antigen isolation, expression, vector construction, cell line cultivation, cGMP protein purification to product fill and finish.... Drug Research > Drug Discovery & Development > Suppliers
Hybrigenics Services - Protein Interactions Expert
Who else knows your protein better than you? Who else knows proteins interactions better than us?... Drug Research > Drug Discovery & Development > Suppliers
LABORATORIOS INIBSA - Pharmaceutical Contract Manufacturing Company
LABORATORIOS INIBSA is a pharmaceutical contract manufacturing company. We have more than 60 years' experience and belong to the INIBSA GROUP. INIBISA supplies products and services to Biotools, Inibsa Dental and Inibsa Hospital, as well as other pharmaceutical companies through our contract manufacturing division. From our facilities in Lliçà de Vall, 20km from Barcelona LABORATORIOS INIBSA currently supplies more than 50 countries worldwide.... Drug Research > Drug Discovery & Development > Suppliers
Chemoswed - Suppliers of Active Pharmaceutical Ingredients
Chemoswed is the reliable Swedish custom synthesis specialist, supplying active ingredients since 1944. With a background in Pharmacia, Chemoswed is since 1996 an independent entity within the DuPont group, offering cost-effective, turn-key solutions to API needs worldwide.We have established unparalleled experience and technology, enabling efficient development and production of quality active pharmaceutical ingredients in quantities from 100 grams to 50 tons.... Drug Research > Drug Discovery & Development > Suppliers
Novo Nordisk Pharmatech A/S - Insulin Human and Benzalkonium Chloride Products
Novo Nordisk Pharmatech A/S is a Novo Nordisk company that specialises in the supply of ingredients for the biopharmaceutical and pharmaceutical industries, such as insulin human for cell culture media and cGMP manufactured quaternary ammonium compounds (usually referred to as quats) such as benzalkonium chloride, cetrimide and cetrimonium bromide.... Drug Research > Drug Discovery & Development > Suppliers
See more

PBR White Paper Recommendations

FlexyCUBE Product Catalog By SYSTAG
SYSTAG - Your Partner in Chemical Development... Drug Research > Drug Discovery & Development > White Papers A Survival Guide to Temperature Data in Life Sciences, by Almac By Almac
Regulations continue to evolve globally within the distribution arena of the Life Sciences industry. Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01)1 as well as Good Distribution Practices Supply Chain Integrity2 has made the most significant impact. There is an increased focus on companies being able to prove the quality and integrity of their drug product throughout the entire supply chain. The industry is facing stricter compliance demands from regulations and regulatory agencies are not always given clear guidance.... Drug Research > Drug Discovery & Development > White Papers Almac: Changing the Dynamics of Temperature Controlled Shipping Solutions By Almac
In the typical clinical trial today, the cost of shipping and distributing supplies accounts for approximately 60 percent of the overall clinical supply chain. And when the cost of product spoilage from temperature excursions is added into the mix, it is no wonder that pharmaceutical companies, Clinical Research Organizations (CROs), and logistics vendors are all eagerly searching for efficiencies and ways to carve costs out of the process.... Drug Research > Drug Discovery & Development > White Papers Almac Explores Interactive Response Technology: An Untapped Source of Historical and Real-Time Data for Risk-Based Monitoring By Almac
Risk-based monitoring has attracted the support of a diverse group of organisations in recent years. Regulators have released guidance encouraging the use of risk-based approaches to clinical trial quality, vendors have created technologies to support such methods, and large pharma companies have pooled their resources to drive adoption. Yet, despite this flurry of activity, the industry has overlooked a potentially useful source of real-time and historical data.... Drug Research > Drug Discovery & Development > White Papers Almac Presents Modern Perspectives on Peptide Synthesis, an Introduction By Almac
The complexity of synthetic peptide products, whether as reagents used in research or as therapeutic APIs, is increasing. As researchers understand more about the biochemical systems which are targeted, and invent ever more sophisticated products, manufacturing methods must keep pace. We look in this article at a number of challenging product classes, the specific problems they present, and potential solutions: Long peptides; Multi-peptide cocktails; Site-specifically modified products.... Drug Research > Drug Discovery & Development > White Papers See more
1-15 of 5521 results